InMed Pharmaceuticals Inc (INM)

[Fress]

Biosynthesis updates coming.

InMed will be able to commercially scale all 90-100 Cannabinoids to other medical cannabis companies faster and cheaper and cleaner than growing the plant. This is so disruptive to the whole industry. Remember Eli Lilly executives Ben Patterson and Martin Bott along with the government of Canada and University of British Colombia.


Some cannabinoids are so rare they can cost $100,000 a gram


Genentech-lilly-The global diabetes pandemic has turned that single innovation in the early 1970s into a $35 billion a year industry today. That small company discovered biosynthetic insulin was Genentech.

Genentech ended up partnering with Eli Lilly to produce biosynthetic insulin and both companies grew steadily ever since.

Eli Lilly is now a $73 billion pharmaceutical giant.

InMed is getting very close to commercially scale there Biosynthesis platform in 2019


https://investors.inmedpharma.com/2018-12-04-InMed-Pharmaceuticals-Receives-Funding-from-the-Government-of-Canada-to-Support-Development-of-Novel-Cannabinoid-Biosynthesis-Program



Dr Yadav Biosynthesis

https://investors.inmedpharma.com/2018-09-10-InMed-Files-Patent-Application-for-its-Cannabinoid-Biosynthesis-Program


https://www.inmedpharma.com/science/biosynthesis/


$25 Million in cash runway into 2021


IMLFF